Glomerulonephritis Clinical Trial
Official title:
An Open-label, Phase 2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 in Subjects With IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G)
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of KP104 in participants with IgAN and C3G. The study will start with enrolling the IgAN cohort. Approximately 42 participants with IgAN will be enrolled in 2 stages: Stage 1 will be used to collect safety, immunogenicity, PK, and PD data to select the optimal biologic dose (OBD) of KP104 for IgAN, as well as to preliminarily explore the effect of KP104 on C3G. Stage 2 will be used to collect safety, immunogenicity, PK, PD, and efficacy data at the OBD dose of KP104 for IgAN and C3G. As soon as the OBD for IgAN is determined, eligible participants with C3G will be enrolled and dosed at the OBD for IgAN for a minimum of 48 weeks for weekly maintenance dosing and a minimum of 47 weeks for biweekly maintenance dosing. Approximately 10 participants with C3G will be enrolled.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001457 -
Lamivudine for Chronic Hepatitis B
|
Phase 2 | |
| Recruiting |
NCT05505955 -
Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency
|
Phase 1 | |
| Recruiting |
NCT01240564 -
The Nephrotic Syndrome Study Network (NEPTUNE)
|
N/A | |
| Active, not recruiting |
NCT05174221 -
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
|
Phase 1 | |
| Completed |
NCT00426348 -
A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
|
Phase 4 | |
| Recruiting |
NCT04662723 -
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
|
Phase 4 | |
| Completed |
NCT02700516 -
Recurrent Glomerulonephritis After Renal Transplantation
|
N/A | |
| Recruiting |
NCT00862693 -
Calcitriol in the Treatment of Immunoglobulin A Nephropathy
|
Phase 4 | |
| Completed |
NCT00983034 -
The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy
|
N/A | |
| Completed |
NCT00004990 -
Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis
|
Phase 2 | |
| Recruiting |
NCT04846010 -
Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
|
Phase 1/Phase 2 | |
| Terminated |
NCT04387448 -
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
|
Phase 2 | |
| Terminated |
NCT04950114 -
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
|
Phase 2 | |
| Completed |
NCT00437463 -
Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor
|
Phase 3 | |
| Terminated |
NCT02523768 -
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
|
Phase 4 | |
| Completed |
NCT00106561 -
Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney
|
Phase 2/Phase 3 | |
| Completed |
NCT04733040 -
Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)
|
Phase 2 | |
| Completed |
NCT00001676 -
Cyclophosphamide and Fludarabine to Treat Lupus Nephritis
|
Phase 1 | |
| Recruiting |
NCT02063100 -
Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis
|
Phase 4 | |
| Completed |
NCT01093157 -
A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy
|
Phase 1/Phase 2 |